Treatment of End Stage Heart Failure Related to Cardiac Amyloidosis

Amyloidosis is a disease characterized by deposition of extracellular proteinaceous mate‐ rial known as amyloid in tissues. Amyloidoses are classified according to the protein composition and the clinical characteristics of the disease [1]. Amyloid protein can accu‐ mulate at various speeds in multiple organ systems and the disease can have localized or systemic manifestations depending on organ involvement. Amyloidotic cardiomyopathy or cardiac amyloidosis is characterized as a restrictive cardiomyopathy associated with in‐ creased ventricular wall thickness caused by the accumulation of amyloid in the heart [2].Cardiac amyloidosis is of special interest since its occurrence usually has a significant impact on morbidity and prognosis.